The Engine Behind Your Next Therapies
7 Therapeutics solves the pre-clinical bottleneck blocking the front end of bringing new radiotheranostic cancer therapies into the clinic and then to market with:
· A proprietary platform for sourcing promising targeting agents
· An efficient de-risking engine to rapidly qualify multiple targeting agent-radioisotope combinations in parallel, and
· An experienced team to build the pre-clinical package to support entry into the clinic.
We clear the path so that promising new therapies can reach the patients who need them.
Leadership Built to Deliver
Aidan Kelly, MBA ‘27
CEO
Five years in drug development, three of them in radiopharmaceuticals. Drove antibody radiotheranostic from lead to first-in-human studies.
Chin-Tu Chen, PhD
Chairman
Professor of Radiology, Medical Physics & Cancer Biology at UChicago. PI of the FMI&T Laboratory: the source program.
Tom Fitzpatrick
Lead Director
Startup founder, advisor, and investor with decades of involvement in imaging and radiomedicine, beginning with BIR Inc., the inventor of 2nd generation CT.